A BRAF mutation can be detected in approximately 45% of all patients with histologically confirmed PTC [18] and is associated with a more aggressive disease course, which includes presence of extrathyroidal infiltration, lymph node metastasis, loss of radioiodine avidity, and higher probability of recurrent disease [19–21]. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.